Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Abivax (ABVX) EUR0.01

Sell:€30.80 Buy:€32.00 Change: €0.20 (0.63%)
Market closed |  Prices as at close on 20 September 2021 | Switch to live prices |
Sell:€30.80
Buy:€32.00
Change: €0.20 (0.63%)
Market closed |  Prices as at close on 20 September 2021 | Switch to live prices |
Sell:€30.80
Buy:€32.00
Change: €0.20 (0.63%)
Market closed |  Prices as at close on 20 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Contact details

Address:
5, rue de la Baume
PARIS
75008
France
Telephone:
+33 (1) 53830841
Website:
https://www.abivax.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ABVX
ISIN:
FR0012333284
Market cap:
€527.48 million
Shares in issue:
14.31 million
Sector:
Biotechnology
Exchange:
Euronext Paris
Country:
France
Currency:
Euro
Indices:
n/a

Key personnel

  • Philippe Pouletty
    Chairman of the Board
  • Hartmut Ehrlich
    Chief Executive Officer
  • Didier Blondel
    Chief Financial Officer, Board Secretary
  • Karl Birthistle
    Vice President Chief Medical Officer and Vice President Clinical & Regulatory Affairs
  • Bernard Fanget
    Vice President - Process Development and Manufacturing
  • Alexandra Pearce
    Vice President and Head of Regulatory Affairs
  • Didier Scherrer
    Vice President - Research & Development Small Molecules
  • Vincent Serra
    Vice President - Research & Development Viral Vaccines
  • Pierre Courteille
    Vice President - Business Development, Chief Commercial Officer
  • Sophie Biguenet
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.